Calcium-independent inhibition of PCSK9 by affinity-improved variants of the LDL receptor EGF(A) domain

Journal of Molecular Biology

Volumn 422, Issue 5, 2012, Pages 685-696

  Zhang, Yingnan ^a   Zhou, Lijuan ^a   Kong Beltran, Monica ^a   Li, Wei ^a   Moran, Paul ^a   Wang, Jianyong ^a   Quan, Clifford ^a   Tom, Jeffrey ^a   Kolumam, Ganesh ^a   Elliott, J Michael ^a   Skelton, Nicholas J ^a   Peterson, Andrew S ^a   Kirchhofer, Daniel ^a  

^a GENENTECH INC   (United States)

Author keywords

PCSK9 inhibition by EGF(A) domain variants

Indexed keywords

ASPARAGINE; CALCIUM; EPIDERMAL GROWTH FACTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; LYSINE; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHAGE DISPLAY; PRIORITY JOURNAL; WILD TYPE;

EID: 84865699483     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2012.06.018     Document Type: Article

References (37)

1. N.G. Seidah, A.M. Khatib, and A. Prat The proprotein convertases and their implication in sterol and/or lipid metabolism Biol. Chem. 387 2006 871 877
2. J.D. Horton, J.C. Cohen, and H.H. Hobbs PCSK9: a convertase that coordinates LDL catabolism J. Lipid Res. 50 Suppl 2009 S172 S177
3. M. Abifadel, M. Varret, J.P. Rabes, D. Allard, K. Ouguerram, and M. Devillers Mutations in PCSK9 cause autosomal dominant hypercholesterolemia Nat. Genet. 34 2003 154 156
4. J. Cohen, A. Pertsemlidis, I.K. Kotowski, R. Graham, C.K. Garcia, and H.H. Hobbs Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 Nat. Genet. 37 2005 161 165
5. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr, and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N. Engl. J. Med. 354 2006 1264 1272
6. J.C. Chan, D.E. Piper, Q. Cao, D. Liu, C. King, and W. Wang A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates Proc. Natl Acad. Sci. USA 106 2009 9820 9825
7. M. Frank-Kamenetsky, A. Grefhorst, N.N. Anderson, T.S. Racie, B. Bramlage, and A. Akinc Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates Proc. Natl Acad. Sci. USA 105 2008 11915 11920
8. H. Liang, J. Chaparro-Riggers, P. Strop, T. Geng, J.E. Sutton, and D. Tsai Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates J. Pharmacol. Exp. Ther. 340 2012 228 236
9. E.A. Stein, S. Mellis, G.D. Yancopoulos, N. Stahl, D. Logan, and W.B. Smith Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N. Engl. J. Med. 366 2012 1108 1118
10. D. Cunningham, D.E. Danley, K.F. Geoghegan, M.C. Griffor, J.L. Hawkins, and T.A. Subashi Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia Nat. Struct. Mol. Biol. 14 2007 413 419
11. E.N. Hampton, M.W. Knuth, J. Li, J.L. Harris, S.A. Lesley, and G. Spraggon The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain Proc. Natl Acad. Sci. USA 104 2007 14604 14609
12. D.E. Piper, S. Jackson, Q. Liu, W.G. Romanow, S. Shetterly, and S.T. Thibault The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol Structure 15 2007 545 552
13. N.G. Seidah, S. Benjannet, L. Wickham, J. Marcinkiewicz, S.B. Jasmin, and S. Stifani The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation Proc. Natl Acad. Sci. USA 100 2003 928 933
14. H.J. Kwon, T.A. Lagace, M.C. McNutt, J.D. Horton, and J. Deisenhofer Molecular basis for LDL receptor recognition by PCSK9 Proc. Natl Acad. Sci. USA 105 2008 1820 1825
15. M.C. McNutt, T.A. Lagace, and J.D. Horton Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells J. Biol. Chem. 282 2007 20799 20803
16. D.W. Zhang, T.A. Lagace, R. Garuti, Z. Zhao, M. McDonald, and J.D. Horton Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation J. Biol. Chem. 282 2007 18602 18612
17. M.J. Bottomley, A. Cirillo, L. Orsatti, L. Ruggeri, T.S. Fisher, and J.C. Santoro Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants J. Biol. Chem. 284 2009 1313 1323
18. M.C. McNutt, H.J. Kwon, C. Chen, J.R. Chen, J.D. Horton, and T.A. Lagace Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells J. Biol. Chem. 284 2009 10561 10570
19. P.L. Surdo, M.J. Bottomley, A. Calzetta, E.C. Settembre, A. Cirillo, and S. Pandit Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH EMBO Rep. 12 2011 1300 1305
20. K.M. Timms, S. Wagner, M.E. Samuels, K. Forbey, H. Goldfine, and S. Jammulapati A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree Hum. Genet. 114 2004 349 353
21. M. Liu, G. Wu, J. Baysarowich, M. Kavana, G.H. Addona, and K.K. Bierilo PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain J Lipid Res. 51 2010 2611 2618
22. A. Roubtsova, M.N. Munkonda, Z. Awan, J. Marcinkiewicz, A. Chamberland, and C. Lazure Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue Arterioscler Thromb Vasc Biol. 31 2011 785 791
23. L. Shan, L. Pang, R. Zhang, N.J. Murgolo, H. Lan, and J.A. Hedrick PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide Biochem. Biophys. Res. Commun. 375 2008 69 73
24. J. Stenflo, Y. Stenberg, and A. Muranyi Calcium-binding EGF-like modules in coagulation proteinases: function of the calcium ion in module interactions Biochim. Biophys. Acta 1477 2000 51 63
25. S. Malby, R. Pickering, S. Saha, R. Smallridge, S. Linse, and A.K. Downing The first epidermal growth factor-like domain of the low-density lipoprotein receptor contains a noncanonical calcium binding site Biochemistry 40 2001 2555 2563
26. S. Saha, J. Boyd, J.M. Werner, V. Knott, P.A. Handford, I.D. Campbell, and A.K. Downing Solution structure of the LDL receptor EGF-AB pair: a paradigm for the assembly of tandem calcium binding EGF domains Structure 9 2001 451 456
27. M.D. Ballinger, J.T. Jones, J.A. Lofgren, W.J. Fairbrother, R.W. Akita, M.X. Sliwkowski, and J.A. Wells Selection of heregulin variants having higher affinity for the ErbB3 receptor by monovalent phage display J. Biol. Chem. 273 1998 11675 11684
28. D.C. Roopenian, and S. Akilesh FcRn: the neonatal Fc receptor comes of age Nat. Rev., Immunol. 7 2007 715 725
29. E.A. Kabat, T.T. Wu, M. Redi-Miller, H.M. Perry, and K.S. Gottesman Sequences of Proteins of Immunological Interest 4 ed. 1987 National Institutes of Health Bethesda, MD
30. P.A. Handford, M. Mayhew, M. Baron, P.R. Winship, I.D. Campbell, and G.G. Brownlee Key residues involved in calcium-binding motifs in EGF-like domains Nature 351 1991 164 167
31. Z. Rao, P. Handford, M. Mayhew, V. Knott, G.G. Brownlee, and D. Stuart The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions Cell 82 1995 131 141
32. R.D. Finn, J. Mistry, J. Tate, P. Coggill, A. Heger, and J.E. Pollington The Pfam protein families database Nucleic Acids Res. 38 2010 D211 D222
33. Y.G. Ni, S. Di Marco, J.H. Condra, L.B. Peterson, W. Wang, and F. Wang A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo J. Lipid Res. 52 2011 78 86
34. N.J. Skelton, M.F. Koehler, K. Zobel, W.L. Wong, S. Yeh, and M.T. Pisabarro Origins of PDZ domain ligand specificity. Structure determination and mutagenesis of the Erbin PDZ domain J. Biol. Chem. 278 2003 7645 7654
35. R. Tonikian, Y. Zhang, C. Boone, and S.S. Sidhu Identifying specificity profiles for peptide recognition modules from phage-displayed peptide libraries Nat. Protoc. 2 2007 1368 1386
36. T.A. Kunkel, J.D. Roberts, and R.A. Zakour Rapid and efficient site-specific mutagenesis without phenotypic selection Methods Enzymol. 154 1987 367 382
37. E. Atherton, D. Harkiss, C. Logan, R. Sheppard, and B. Williams A mild procedure for solid phase peptide synthesis: use of fluorenylmethoxycarbonylamino-acids J. Chem. Soc. Chem. Commun. 13 1978 537 539